Roche Wins FDA Clearance for Elecsys pTau217 Test
INDIANAPOLIS, U.S., Aug 28, 2026 Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based...
pTau217
Advertisement
Quest Diagnostics Adds Roche pTau217 Blood Test to AD Portfolio
Secaucus, New Jersey, August 24, 2026 Quest Diagnostics announced new developments in its Quest AD-Detect® blood-testing portfolio, expanding access...
Annovis Advances Buntanetap in Alzheimer’s Phase 3
Malvern, Pennsylvania — August 14, 2026 Annovis Bio, Inc. announced that its pivotal Phase 3 Alzheimer’s disease trial of...
ALZpath Expands Global Leadership in Alzheimer’s Blood Biomarkers
CARLSBAD, California, July 13, 2026 ALZpath, Inc. has announced a major scientific milestone at the Alzheimer’s Association International Conference...
NIH Develops Blood Test to Predict Alzheimer’s Disease Progression
BETHESDA, Md., July 1, 2026 A National Institutes of Health (NIH)-funded study has identified a promising blood-based biomarker that...
Advertisements
Roche Gains CE Mark Approval for Elecsys pTau217 Test
BASEL, Switzerland, May 12, 2026 Roche announced that it has received European CE Mark approval for Elecsys® plasma phosphorylated-tau...
Fujirebio Launches Automated pTau217 CSF Assay for Alzheimer’s Research
Tokyo, Japan – January 28, 2026 – Fujirebio, a global leader in in vitro diagnostics and part of H.U....
Alamar Biosciences Launches Blood-Based pTau217 Assay for Alzheimer’s Research
FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a leader in precision proteomics, today announced the launch of...
Advertisement
